Marshall Wace LLP Increases Position in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Marshall Wace LLP grew its holdings in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 52.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 110,304 shares of the company’s stock after purchasing an additional 37,810 shares during the period. Marshall Wace LLP owned approximately 0.17% of Larimar Therapeutics worth $427,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Barclays PLC boosted its holdings in Larimar Therapeutics by 321.2% in the third quarter. Barclays PLC now owns 60,032 shares of the company’s stock worth $393,000 after acquiring an additional 45,781 shares in the last quarter. Virtu Financial LLC bought a new position in Larimar Therapeutics in the 3rd quarter worth about $71,000. JPMorgan Chase & Co. grew its position in Larimar Therapeutics by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock valued at $143,000 after purchasing an additional 3,425 shares during the last quarter. SG Americas Securities LLC increased its stake in Larimar Therapeutics by 35.1% during the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company’s stock valued at $75,000 after purchasing an additional 5,042 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Larimar Therapeutics in the fourth quarter worth about $52,000. 91.92% of the stock is owned by institutional investors.

Larimar Therapeutics Trading Up 3.8 %

Shares of LRMR stock opened at $2.97 on Friday. The company has a 50 day simple moving average of $2.36 and a two-hundred day simple moving average of $4.23. The stock has a market cap of $190.16 million, a P/E ratio of -2.58 and a beta of 0.91. Larimar Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR) last announced its earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). As a group, equities analysts forecast that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on LRMR. Citigroup reissued a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Robert W. Baird decreased their price target on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Guggenheim reaffirmed a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. HC Wainwright boosted their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, March 25th. Finally, Truist Financial started coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Larimar Therapeutics presently has an average rating of “Buy” and a consensus target price of $19.63.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.